Complete Remission After Combination Chemotherapy for Stage Iv Gastric Cancer With Peritoneal Dissemination and Liver Metastases

Mukai, Masaya; Hinoki, Tomoya; Tajima, Takayuki; Nakasaki, Hisao; Sato, Shinkichi; Okamoto, Y.; Ogoshi, Kyoji; Makuuchi, Hiroyasu

doi:10.4993/acrt1992.11.169

Cited by 4 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity of Asians to the effects of oral anticancer agents is assumed to be higher than that of Westerners because of low expression of TS/DPD. Oral anticancer agents have the great advantage making treatment at home possible and improving QOL because frequent outpatient visits are not required, as well as having a lower cost (26,37,38). However, unlike intravenous administration with confirmation by physicians and nurses, a major problem is that it remains unclear whether or not correct administration has actually occurred even when patients make entries in medication notebooks or complete questionnaires.…”

Section: Discussionmentioning

confidence: 99%

Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer

Mukai

Kishima²,

Uchiumi³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. The aim of this study was to evaluate the quality of life (QOL) from the performance status (PS) and face scale (FS), and to compare adverse events (AEs) during chemotherapy in 28 patients with node-positive colorectal cancer (NP-CRC) and 15 patients with node-positive gastric cancer (NP-GC). The anticancer regimen consisted of 5-FU/ LV+CPT-11 for NP-CRC and 5-FU+low-dose CDDP for NP-GC. Results were evaluated after completion of three courses. QOL evaluation revealed no significant differences between the two groups with respect to PS and FS. Among hematological AEs, grade 1/2 mild leucopenia was significantly more common in NP-CRC than NP-GC patients (p<0.05), while grade 1/2 mild thrombocytopenia was significantly more common in NP-GC than NP-CRC patients (p<0.05). Among non-hematological AEs, grade 1/2 mild neuropathy (olfactory nerve) was significantly more common in NP-CRC than NP-GC patients (p<0.05). The monthly cost for one course was ~€586.8 for NP-CRC patients and ~€181.8 for NP-GC patients. These results suggest that first-line postoperative outpatient adjuvant chemotherapy for NP-CRC and NP-GC shows no significant differences with respect to QOL, but both AEs and the cost are higher for NP-CRC than for NP-GC.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer

Mukai

Kishima²,

Uchiumi³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Patients with stage III colorectal cancer were treated with 350 mg/m 2 of 5-fluorouracil (5-FU) and 150 mg/m 2 of leucovorin (LV) 5 times weekly by intravenous infusion for six months, followed by oral administration of UFT plus PSK for 2.5 years (21,22). Patients who had stage II/III gastric cancer were treated with 350 mg/m 2 of 5-FU and low-dose cisplatin (CDDP; 5 mg/m 2 ) 5 times weekly by intravenous infusion for six months, followed by oral administration of UFT plus PSK for 2.5 years (23,24).…”

Section: Methodsmentioning

confidence: 99%

Prospective study on the recurrence/metastasis of stage II/III colorectal cancer and gastric cancer associated with occult neoplastic cells in lymph node sinuses: Three-year interim results

Mukai

Tajima²,

Sato³

et al. 2006

Oncol Rep

Self Cite

View full text Add to dashboard Cite

This study was designed to prospectively examine whether the presence of occult neoplastic cells (ONCs) in lymph nodes or positive high-risk (HR) criteria were related to the survival of patients with stage II/III colorectal cancer or gastric cancer. The 3-year relapse-free survival (3Y-RFS) rate was calculated for 79 patients who were registered during a 2-year period. The 3Y-RFS rate was 80.5% in patients without ONCs (n=54) and 84.3% in patients with ONCs (n=25; p=0.9089). Among patients who had stage II/III colorectal cancer, it was 89.0% (n=47) and 76.2% (n=15), respectively (p=0.4131). For patients with stage III colorectal cancer alone, it was 80.8% (n=24) and 62.5% (n=9), respectively (p=0.4006). The 3Y-RFS rate was respectively 88.1% and 77.6% for the HR patients (n=31) and low-risk (LR) patients (n=48) with stage II/III colorectal cancer or gastric cancer (p=0.5545). It was respectively 92.3% and 84.3% for the HR patients (n=20) and LR patients (n=42) with stage II/III colorectal cancer (p=0.5073). Also, the rate was respectively 80% and 76.2% for the HR patients (n=7) and LR patients (n=26) with stage III colorectal cancer alone (p=0.9506). These results indicate that the 3Y-RFS rate is lower in ONC-positive patients with stage II/III colorectal cancer, suggesting that ONCs may have an influence on survival.

show abstract

“…As shown in Fig. 1, the hyperpigmentation has been possibly found to show strong symptoms in the face and hand [21,22]. For this reason, in order to understand the optical characteristics of hyperpigmentation, we chose cheek with a large hyperpigmentation area where measurement can be performed easily.…”

Section: Japanese People With Hyperpigmentationmentioning

confidence: 99%

Optical characteristics of human skin with hyperpigmentation caused by fluorinated pyrimidine anticancer agent

Kono

Imanishi

Nozawa³

et al. 2019

Biomed. Opt. Express

View full text Add to dashboard Cite

The fluorinated pyrimidine anticancer agent has several side effects that degrade the quality of life of patients, including hyperpigmentation. Hyperpigmentation differs in color from common pigmentation such as a suntan, giving rise to dramatic skin appearance changes. In this study, we measured the optical properties of the skin of patients with hyperpigmentation by using the reflection spatial profile method (RSPM). The absorption coefficient in hyperpigmentation increased ~1.5-2.5 times and pheomelanin significantly increased compared to the normal skin. In addition, the scattering coefficient of skin with hyperpigmentation was about 65.9-76.5% of that of normal skin.

show abstract

Complete Remission After Combination Chemotherapy for Stage Iv Gastric Cancer With Peritoneal Dissemination and Liver Metastases

Cited by 4 publications

References 13 publications

Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer

Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer

Prospective study on the recurrence/metastasis of stage II/III colorectal cancer and gastric cancer associated with occult neoplastic cells in lymph node sinuses: Three-year interim results

Optical characteristics of human skin with hyperpigmentation caused by fluorinated pyrimidine anticancer agent

Contact Info

Product

Resources

About